☆ 4.4 Review

Assessment of treatment response in hepatocellular carcinoma: a review of the literature

FUTURE ONCOLOGY (2013)

期刊

FUTURE ONCOLOGY

卷 9, 期 6, 页码 845-854

出版社

FUTURE MEDICINE LTD

DOI: 10.2217/FON.13.33

关键词

hepatocellular carcinoma; mRECIST; response criteria

类别

Oncology

向作者/读者索取更多资源

Protocol

Reagent

摘要

Hepatocellular carcinoma (HCC) has a high incidence all over the world. Even if the primary end point of treatment of HCC is survival, radiological response could be a surrogate end point of survival, and could have a key role in clinical management. Since 1950 several radiological response criteria have been applied; however, it was not until 2000 that specific criteria for HCC were introduced by the European Association for the Study of the Liver (EASL), and these were then standardized in 2010 with the development of the modified Response Evaluation Criteria for Solid Tumors (mRECIST) for HCC. The purpose of this brief review is to compare data in literature regarding the application and the performance of mRECIST in clinical practice, and to discuss unclear and open issues.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Radiology, Nuclear Medicine & Medical Imaging

Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib

Osman Oecal, Kerstin Schuette, Christoph J. Zech, Christian Loewe, Otto van Delden, Vincent Vandecaveye, Chris Verslype, Bernhard Gebauer, Christian Sengel, Irene Bargellini, Roberto Iezzi, Alexander Philipp, Thomas Berg, Heinz J. Kluempen, Julia Benckert, Maciej Pech, Antonio Gasbarrini, Holger Amthauer, Peter Bartenstein, Bruno Sangro, Peter Malfertheiner, Jens Ricke, Max Seidensticker

Summary: In patients with advanced hepatocellular carcinoma receiving sorafenib treatment, the combination with radioembolization can enhance tumor response without prolonging survival. Better patient selection and selective treatment could potentially improve outcomes after combination therapy.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Optimal imaging criteria and modality to determine Milan criteria for the prediction of post-transplant HCC recurrence after locoregional treatment

Nieun Seo, Dong Jin Joo, Mi-Suk Park, Seung-seob Kim, Hye Jung Shin, Yong Eun Chung, Jin-Young Choi, Myoung Soo Kim, Myeong-Jin Kim

Summary: The study aimed to investigate the optimal radiologic method for determining Milan criteria (MC) in predicting post-liver transplantation (LT) recurrence in hepatocellular carcinoma (HCC) patients. The findings showed that MRI with mRECIST was the optimal method in predicting recurrence, with higher accuracy and sensitivity compared to CT with LI-RADS TRA or MRI with mRECIST.

EUROPEAN RADIOLOGY (2023)

添加到收藏夹

Article Oncology

Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib

Osman Oecal, Regina Schinner, Kerstin Schuette, Enrico N. de Toni, Christian Loewe, Otto van Delden, Vincent Vandecaveye, Bernhard Gebauer, Christoph J. Zech, Christian Sengel, Irene Bargellini, Antonio Gasbarrini, Bruno Sangro, Maciej Pech, Peter Malfertheiner, Jens Ricke, Max Seidensticker

Summary: The study aimed to explore the relationship between follow-up imaging characteristics and overall survival in advanced HCC patients under sorafenib treatment. Objective response and early tumor shrinkage were found to be independent prognostic factors for OS in patients with HCC.

CANCER IMAGING (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study

Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang-Hyub Han, Kenji Ikeda, Ann-Lii Cheng, Arndt Vogel, Francesco Tovoli, Kazuomi Ueshima, Hiroshi Aikata, Carlos Lopez Lopez, Marc Pracht, Zhiqiang Meng, Bruno Daniele, Joong-Won Park, Daniel Palmer, Toshiyuki Tamai, Kenichi Saito, Corina E. Dutcus, Riccardo Lencioni

Summary: The study aimed to validate objective response as an independent predictor of overall survival (OS) in individuals with unresectable hepatocellular carcinoma (HCC) receiving systemic anti-angiogenic therapy. The results showed that objective response assessed by investigator-assessed mRECIST could predict the survival of patients. Further studies are needed to confirm this finding.

JOURNAL OF HEPATOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Impact of radiological response and pattern of progression in patients with hepatocellular carcinoma treated by atezolizumab- bevacizumab

Claudia Campani, Ariane Vallot, Haroun Ghannouchi, Manon Allaire, Manon Evain, Philippe Sultanik, Sabrina Sidali, Lorraine Blaise, Dominique Thabut, Pierre Nahon, Olivier Seror, Nathalie Ganne-Carrie, Jean-Charles Nault, Mathilde Wagner, Olivier Sutter

Summary: This study aims to assess the role of radiological response to atezolizumab-bevacizumab in patients with hepatocellular carcinoma (HCC) in predicting overall survival (OS). The results showed significant differences in disease progression among patients evaluated by RECIST 1.1 and mRECIST criteria, with mRECIST identifying more responders. Additionally, the presence of new extrahepatic lesions or vascular invasion was associated with a poorer prognosis.

HEPATOLOGY (2023)

添加到收藏夹

Article Oncology

Analysis of Lenvatinib's Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma

Kei Amioka, Tomokazu Kawaoka, Takahiro Kinami, Shintaro Yamasaki, Masanari Kosaka, Yusuke Johira, Shigeki Yano, Kensuke Naruto, Yuwa Ando, Yasutoshi Fujii, Shinsuke Uchikawa, Atsushi Ono, Masami Yamauchi, Michio Imamura, Yumi Kosaka, Kazuki Ohya, Nami Mori, Shintaro Takaki, Keiji Tsuji, Keiichi Masaki, Yoji Honda, Hirotaka Kouno, Hioshi Kohno, Kei Morio, Takashi Moriya, Noriaki Naeshiro, Michihiro Nonaka, Yasuyuki Aisaka, Takahiro Azakami, Akira Hiramatsu, Hiroshi Aikata, Shiro Oka

Summary: This study investigated the efficacy of lenvatinib and its combination with TACE in patients with intermediate-stage unresectable hepatocellular carcinoma (u-HCC). The results demonstrated the efficacy of lenvatinib and confirmed that further improvements in prognosis could be obtained with TACE after lenvatinib induction. This suggests that considering the combination of lenvatinib and TACE may be important for improving the prognosis of intermediate-stage u-HCC patients.

CANCERS (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Evaluation of the LI-RADS treatment response algorithm in hepatocellular carcinoma after trans-arterial chemoembolization

Andrea S. Kierans, Marc Najjar, Silvina P. Dutruel, Alexander Gavlin, Christine Chen, Michael J. Lee, Gulce Askin, Karim J. Halazun

Summary: The LI-RADS treatment response algorithm (LR-TRA) and modified RECIST (mRECIST) showed no significant difference in diagnostic performance for detecting viable HCC after TACE on MRI, with LR-TRA demonstrating high specificity and moderate sensitivity for this purpose in a North American cirrhotic cohort.

CLINICAL IMAGING (2021)

添加到收藏夹

Article Oncology

Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy

Hidekatsu Kuroda, Takayoshi Oikawa, Masashi Ninomiya, Masashi Fujita, Kazumichi Abe, Kazuo Okumoto, Tomohiro Katsumi, Wataru Sato, Go Igarashi, Chikara Iino, Tetsu Endo, Nobukazu Tanabe, Hiroshi Numao, Shinsaku Fukuda, Katsunori Iijima, Atsushi Masamune, Hiromasa Ohira, Yoshiyuki Ueno, Yasuhiro Takikawa

Summary: This study compared the efficacy and safety of Lenvatinib-transcatheter arterial chemoembolization (LEN-TACE) sequential therapy to LEN monotherapy in patients with unresectable hepatocellular carcinoma (u-HCC). The results showed that the LEN-TACE group had significantly higher overall survival (OS) and progression-free survival (PFS) compared to the LEN monotherapy group. The initial response to LEN treatment was identified as an independent factor contributing to the deep response in LEN-TACE sequential therapy.

LIVER CANCER (2022)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study

Rie Sugimoto, Takeaki Satoh, Akihiro Ueda, Takeshi Senju, Yuki Tanaka, Shinsaku Yamashita, Toshimasa Koyanagi, Tomoyuki Kurashige, Nobito Higuchi, Tsukasa Nakamura, Masatake Tanaka, Yuuki Azuma, Akari Ohno, Aritsune Ooho, Mari Ooe, Taiji Mutsuki, Koutarou Uchimura, Masami Kuniyoshi, Seiya Tada, Yoshifusa Aratake, Tsuyoshi Yoshimoto, Naoki Yamashita, Shigeru Harada, Makoto Nakamuta, Kenta Motomura, Motoyuki Kohjima

Summary: This study evaluated the efficacy of atezolizumab plus bevacizumab treatment in hepatocellular carcinoma patients previously treated with molecular targeted agents. Different molecular targeted agents had different treatment responses, and the combination of atezolizumab and bevacizumab may lead to rapid tumor growth followed by shrinkage.

MEDICINE (2022)

添加到收藏夹

Review Oncology

Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights

Antonella Cammarota, Valentina Zanuso, Tiziana Pressiani, Nicola Personeni, Lorenza Rimassa

Summary: Management of advanced hepatocellular carcinoma (HCC) has become increasingly complex with the introduction of novel therapies. The assessment and monitoring of systemic treatment response are essential for clinical trials and practice. Parameters such as progression-free survival and objective response rate provide early information on treatment efficacy. However, none of them can replace overall survival as a surrogate endpoint. Tumor assessment relies on the Response Evaluation Criteria for Solid Tumors (RECIST), but modified criteria more accurately capture HCC response. Prognosticators and novel imaging techniques are being explored for better treatment response evaluation.

JOURNAL OF HEPATOCELLULAR CARCINOMA (2022)

添加到收藏夹

Article Oncology

Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies

Masatoshi Kudo, Robert Montal, Richard S. Finn, Florian Castet, Kazuomi Ueshima, Naoshi Nishida, Philipp K. Haber, Youyou Hu, Yasutaka Chiba, Myron Schwartz, Tim Meyer, Riccardo Lencioni, Josep M. Llovet

Summary: This study analyzed the correlation between objective response and overall survival in patients with advanced hepatocellular carcinoma (HCC). The results showed that OR-mRECIST is an independent predictor of overall survival and can be used as an endpoint in early-phase trials.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Correlation of tumor response on CT with pathologically proven necrosis in hepatocellular carcinoma treated by conventional transcatheter arterial chemoembolization: threshold value of intratumoral Lipiodol accumulation predicting tumor necrosis

Chan Park, Dong Il Gwon, Hee Ho Chu, Jong Woo Kim, Jin Hyoung Kim, Gi-Young Ko

Summary: The study evaluated associations between pathology and CT assessments according to mRECIST in HCC treated by cTACE. The only significant predictor of complete necrosis in the dataset was mean HU of lipiodol accumulation. A threshold value for lipiodol accumulation >460 HU was highly sensitive and specific for complete necrosis.

ABDOMINAL RADIOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Liver MRI and clinical findings to predict response after drug eluting bead transarterial chemoembolization in hepatocellular carcinoma

Jeong Yeop Lee, Byung Chan Lee, Hyoung Ook Kim, Suk Hee Heo, Sang Soo Shin, Yong Yeon Jeong

Summary: This study identified heterogeneous signal intensity and elevated AFP level as important predictors for treatment response and disease-free survival after DEB-TACE in patients with hepatocellular carcinoma.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Oncology

Characterization of response to atezolizumab plus bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial

Riad Salem, Daneng Li, Nicolas Sommer, Sairy Hernandez, Wendy Verret, Beiying Ding, Riccardo Lencioni

Summary: The IMbrave150 trial demonstrated significant improvement in clinical outcomes with atezolizumab + bevacizumab compared to sorafenib in unresectable hepatocellular carcinoma patients, showing higher objective response rate and deeper response depth.

CANCER MEDICINE (2021)

添加到收藏夹

Article Oncology

Predictive Factors of Complete Response to Transarterial Chemoembolization in Intermediate Stage Hepatocellular Carcinoma beyond Up-To-7 Criteria

Natsuhiko Saito, Hideyuki Nishiofuku, Takeshi Sato, Shinsaku Maeda, Kiyoyuki Minamiguchi, Ryosuke Taiji, Takeshi Matsumoto, Yuto Chanoki, Tetsuya Tachiiri, Hideki Kunichika, Nagaaki Marugami, Toshihiro Tanaka

Summary: This study aimed to clarify the prognosis and identify predictors for obtaining a complete response (CR) by transarterial chemoembolization (TACE) in intermediate stage HCC beyond up-to-7 criteria. Overall, 56.9% of patients obtained CR, which contributed to prolonging survival. The treatment strategy based on the 7-11 criteria is suggested for intermediate stage HCC.

CANCERS (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19

Fabio Salvatore Macaluso, Alessandra Giuliano, Walter Fries, Anna Viola, Alfredo Abbruzzese, Maria Cappello, Enrica Giuffrida, Lucio Carrozza, Antonino Carlo Privitera, Antonio Magnano, Concetta Ferracane, Giuseppe Scalisi, Maria Giovanna Minissale, Emiliano Giangreco, Serena Garufi, Carmelo Bertolami, Ugo Cucinotta, Francesco Graziano, Angelo Casa, Sara Renna, Giulia Teresi, Giulia Rizzuto, Mariella Mannino, Marcello Maida, Ambrogio Orlando

Summary: This retrospective study found that severe inflammatory bowel disease was an independent risk factor for severe COVID-19. Patients with inflammatory bowel disease did not have a higher risk of SARS-CoV-2 infection compared to the general population, and a worse prognosis was not typically associated with immunomodulatory drugs.

INFLAMMATORY BOWEL DISEASES (2023)

添加到收藏夹

Article Respiratory System

High-flow nasal oxygen versus conventional oxygen therapy in patients with COVID-19 pneumonia and mild hypoxaemia: a randomised controlled trial

Claudia Crimi, Alberto Noto, Fabiana Madotto, Mariachiara Ippolito, Santi Nolasco, Raffaele Campisi, Stefano De Vuono, Giuseppe Fiorentino, Ioannis Pantazopoulos, Athanasios Chalkias, Alessandro Libra, Alessio Mattei, Raffaele Scala, Enrico M. Clini, Begum Ergan, Manel Lujan, Joao Carlos Winck, Antonino Giarratano, Annalisa Carlucci, Cesare Gregoretti, Paolo Groff, Andrea Cortegiani

Summary: Among patients with COVID-19 pneumonia and mild hypoxaemia, the use of HFNO did not significantly reduce the likelihood of escalation of respiratory support.

THORAX (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Effectiveness and safety of 1-L PEG-ASC versus other bowel preparations for colonoscopy: A meta-analysis of nine randomized clinical trials

M. Maida, M. Ventimiglia, A. Facciorusso, A. Vitello, E. Sinagra, G. Marasco

Summary: This meta-analysis evaluated the effectiveness and safety of 1-L PEG-ASC compared to other bowel preparations for colonoscopy. The results showed that 1-L PEG-ASC had higher cleansing success and right-colon high-quality cleansing rates compared to other preparations, with similar adenoma detection rates. However, the incidence of adverse events was higher with 1-L PEG-ASC, although no serious adverse events or deaths occurred.

DIGESTIVE AND LIVER DISEASE (2023)

添加到收藏夹

Article Oncology

Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Lorenza Rimassa, Jose Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Takumi Kawaguchi, Margarida Montes, Caterina Vivaldi, Caterina Solda, Fabio Piscaglia, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Mario Scartozzi, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Antonella Cammarota, Valentina Burgio, Stefano Cascinu, Andrea Casadei-Gardini

Summary: This study compares the response rates of lenvatinib and atezolizumab plus bevacizumab in the first-line treatment of hepatocellular carcinoma (HCC) patients. The results show that lenvatinib achieves higher response rates in all patient subgroups. Patients who achieve complete response with atezolizumab plus bevacizumab can achieve a better overall survival compared to other treatments.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis

Rodolfo Sacco, Daryl Ramai, Raffaella Tortora, Giovan Giuseppe di Costanzo, Michela Emma Burlone, Mario Pirisi, Piera Federico, Bruno Daniele, Marianna Silletta, Paolo Gallo, Caterina Cocuzza, Maurizio Russello, Giuseppe Cabibbo, Gabriele Rancatore, Silvia Cesario, Gianluca Masi, Luca Marzi, Andrea Mega, Alessandro Granito, Giulia Pieri, Edoardo G. G. Giannini, Rosa Paolillo, Gennaro Gadaleta-Caldarola, Vincenzo Dadduzio, Guido Giordano, Luca Giacomelli, Simonetta Papa, Matteo Renzulli, Marcello Maida, Michele Ghidini, Mauro Borzio, Antonio Facciorusso

Summary: Hepatocellular carcinoma is the fifth most common cancer worldwide. Lenvatinib has proven to be an effective option for treating advanced diseases. Our study showed that patients with nonviral etiologies have longer survival than those with viral etiology, which is important for clinical decision-making.

CANCERS (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Safety of endoscopic pancreatic necrosectomy compared with percutaneous and surgical necrosectomy: a nationwide inpatient study

Daryl Ramai, Dan M. McEntire, Kameron Tavakolian, Joseph Heaton, Saurabh Chandan, Banreet Dhindsa, Amaninder Dhaliwal, Marcello Maida, Andrea Anderloni, Antonio Facciorusso, Douglas G. Adler

Summary: This study compared the safety and outcomes of endoscopic, percutaneous, and surgical necrosectomy for pancreatic necrosis. The findings showed that endoscopic necrosectomy had the lowest mortality rate and fewer complications, shorter hospital stays, and lower costs compared to percutaneous and surgical approaches.

ENDOSCOPY INTERNATIONAL OPEN (2023)

添加到收藏夹

Letter Gastroenterology & Hepatology

Letter: Post- -COVID--19 functional dyspepsia and irritable bowel syndrome--Authors' reply

Giovanni Marasco, Marcello Maida, Cesare Cremon, Maria Raffaella Barbaro, Vincenzo Stanghellini, Giovanni Barbara

Summary: This article is connected to Marasco et al papers. To view these articles, visit and...

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

添加到收藏夹

Letter Gastroenterology & Hepatology

Letter: Post- -COVID--19 disorders of gut--brain interaction (DGBI)--just post--infectious or a multifaceted entity? Authors' reply

Giovanni Marasco, Marcello Maida, Cesare Cremon, Maria R. Barbaro, Vincenzo Stanghellini, Giovanni Barbara

Summary: This article is linked to the papers by Marasco et al. To view these articles, visit...

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Meta-analysis: Post-COVID-19 functional dyspepsia and irritable bowel syndrome

Giovanni Marasco, Marcello Maida, Cesare Cremon, Maria Raffaella Barbaro, Vincenzo Stanghellini, Giovanni Barbara

Summary: This meta-analysis aimed to estimate the incidence of post-COVID-19 functional dyspepsia (FD) and irritable bowel syndrome (IBS). The analysis found that COVID-19 survivors are at a higher risk of developing IBS compared to controls, while data for FD are inconclusive.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

添加到收藏夹

Editorial Material Medicine, General & Internal

High-Flow Nasal Therapy in Acute and Chronic Respiratory Failure: Past, Present, and Future

Claudia Crimi, Andrea Cortegiani

JOURNAL OF CLINICAL MEDICINE (2023)

添加到收藏夹

Review Infectious Diseases

Implementation Strategies for Preventing Healthcare-Associated Infections across the Surgical Pathway: An Italian Multisociety Document

Massimo Sartelli, Stefano Bartoli, Felice Borghi, Stefano Busani, Andrea Carsetti, Fausto Catena, Nicola Cillara, Federico Coccolini, Andrea Cortegiani, Francesco Cortese, Elisa Fabbri, Domitilla Foghetti, Francesco Forfori, Antonino Giarratano, Francesco Maria Labricciosa, Pierluigi Marini, Claudio Mastroianni, Angelo Pan, Daniela Pasero, Marco Scatizzi, Bruno Viaggi, Maria Luisa Moro

Summary: Healthcare-associated infections (HAIs) have negative impacts on patients and also incur additional costs to the healthcare system. With the rise of antibiotic resistance, preventing HAIs has become more crucial. It is an important indicator of healthcare quality and patient safety, and should be prioritized by all health systems worldwide.

ANTIBIOTICS-BASEL (2023)

添加到收藏夹

Review Medicine, General & Internal

Diagnosis and Management of Esophagogastric Varices

Socrate Pallio, Giuseppinella Melita, Endrit Shahini, Alessandro Vitello, Emanuele Sinagra, Barbara Lattanzi, Antonio Facciorusso, Daryl Ramai, Marcello Maida

Summary: Acute variceal bleeding is a serious complication of portal hypertension and a common cause of acute upper gastrointestinal bleeding. It represents a major economic and population health issue.

DIAGNOSTICS (2023)

添加到收藏夹

Article Health Care Sciences & Services

Variation in Communication and Family Visiting Policies in Italian Intensive Care Units during the COVID-19 Pandemic: A Secondary Analysis of the COVISIT International Survey

Barbara Simone, Mariachiara Ippolito, Pasquale Iozzo, Francesco Zuccaro, Antonino Giarratano, Maurizio Cecconi, Alexis Tabah, Andrea Cortegiani

Summary: During the COVID-19 pandemic, Italian ICUs implemented restrictions on in-person visiting, with phone calls and virtual meetings being the main means of communication with caregivers.

HEALTHCARE (2023)

添加到收藏夹

Article Oncology

Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis

Ciro Celsa, Giuseppe Cabibbo, David James Pinato, Gabriele Di Maria, Marco Enea, Marco Vaccaro, Salvatore Battaglia, Giacomo Emanuele Maria Rizzo, Paolo Giuffrida, Carmelo Marco Giacchetto, Gabriele Rancatore, Maria Vittoria Grassini, Calogero Camma

Summary: Atezolizumab+Bevacizumab is the standard of care for first-line treatment of advanced HCC. However, there is a lack of direct comparison with other combination treatments including ICI+TKI. This network meta-analysis aims to indirectly compare the efficacy and safety of first-line systemic therapies for unresectable-advanced HCC.

LIVER CANCER (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.